قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Sentencing of Johnson and Johnson Risperdal: Company strikes with $ 8 billion verdict after drug related to growing boy's breast

Sentencing of Johnson and Johnson Risperdal: Company strikes with $ 8 billion verdict after drug related to growing boy's breast



A Philadelphia jury orders Johnson & Johnson medical company to pay $ 8 billion in punitive damages in the case of a man who said he developed breasts after taking the anti-psychotic drug from Risperdal as a child. The case is not about a series of big-money lawsuits the company is facing over baby powder for signature .

In the case of Risperdal, a jury found that Johnson and Johnson failed to alert 26-year-old Nicholas Murray of the side effects of the drug. Murray claims that accepting Risperdal as a child led him to develop a breast, an incurable condition known as gynecomastia. Thousands of others have filed cases claiming the same.

Murray said he was prescribed the drug at the age of 9 for symptoms related to autism spectrum disorder, despite the fact that FDA approval of the drug in the 1

990s was for the treatment of schizophrenia and bipolar episodes obsession with adults.

Lawyers for Murray claim that the company sold the drug for unauthorized use without children to children to increase profits, choosing "billions over children."

Johnson & Johnson denied the allegations and said they were confident the decision would be overturned. In a statement, the company said it was "obstructing the presentation of … key evidence …" The company also said that the evidence showed that the drug label "clearly and correctly outlines the risks associated with the drug".

Murray's lawyers told CBS This Morning Consumer Investigator Anna Werner that punitive damages were intended to deter the company from such behavior in the future. They believe the decision will apply.

© 2019 CBS Interactive Inc. All rights reserved.


Source link